ALLO-EVASION Trademark

Trademark Overview

On Friday, June 4, 2021, a trademark application was filed for ALLO-EVASION with the United States Patent and Trademark Office. The USPTO has given the ALLO-EVASION trademark a serial number of 90980796. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Thursday, February 15, 2024. This trademark is owned by Century Therapeutics, Inc.. The ALLO-EVASION trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific research and development services related to cell-based medical therapies in the field of biotechnology in relation to cancer
allo-evasion

General Information

Serial Number90980796
Word MarkALLO-EVASION
Filing DateFriday, June 4, 2021
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateThursday, February 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 3, 2022

Trademark Statements

Goods and ServicesScientific research and development services related to cell-based medical therapies in the field of biotechnology in relation to cancer

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 26, 2021
Primary Code042
First Use Anywhere DateWednesday, February 8, 2023
First Use In Commerce DateWednesday, February 8, 2023

Trademark Owner History

Party NameCentury Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPhiladelphia, PA 19104
Party NameCentury Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPhiladelphia, PA 19104

Trademark Events

Event DateEvent Description
Thursday, February 15, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, February 15, 2024NON-FINAL ACTION E-MAILED
Thursday, February 15, 2024SU - NON-FINAL ACTION - WRITTEN
Wednesday, January 24, 2024STATEMENT OF USE PROCESSING COMPLETE
Tuesday, December 26, 2023USE AMENDMENT FILED
Wednesday, January 24, 2024DIVISIONAL PROCESSING COMPLETE
Wednesday, December 27, 2023DIVISIONAL REQUEST RECEIVED
Tuesday, December 26, 2023TEAS REQUEST TO DIVIDE RECEIVED
Saturday, January 13, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, December 26, 2023TEAS STATEMENT OF USE RECEIVED
Saturday, June 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 22, 2023SOU EXTENSION 2 GRANTED
Thursday, June 22, 2023SOU EXTENSION 2 FILED
Thursday, June 22, 2023SOU TEAS EXTENSION RECEIVED
Thursday, October 27, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 25, 2022SOU EXTENSION 1 GRANTED
Tuesday, October 25, 2022SOU EXTENSION 1 FILED
Tuesday, October 25, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, June 28, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 3, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 3, 2022PUBLISHED FOR OPPOSITION
Wednesday, April 13, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, March 31, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 22, 2022ASSIGNED TO EXAMINER
Thursday, August 26, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 8, 2021NEW APPLICATION ENTERED

Related Keywords

evasion allo field therapies biotechnology relation cancer medical based development research services